-+ 0.00%
-+ 0.00%
-+ 0.00%

PolyPid reports SHIELD II trial analysis shows D-PLEX100 cuts severe surgical infections 64%

PUBT·04/28/2026 12:32:39
Listen to the news
PolyPid reports SHIELD II trial analysis shows D-PLEX100 cuts severe surgical infections 64%
  • PolyPid scheduled a presentation on May 6, 2026 at Surgical Infection Society 2026 Annual Meeting, featuring a new analysis from Phase 3 SHIELD II trial of D-PLEX100 in abdominal colorectal surgery.
  • Topline SHIELD II results were already reported, with analysis indicating fewer clinically significant surgical wound infections versus standard care.
  • PolyPid also reported that infections occurring despite treatment tended to be less severe, which could reduce need for intensive infection management.
  • Company highlighted potential downstream impact on hospital resource use, including shorter inpatient stays and lower treatment burden.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PolyPid Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202604280830PRIMZONEFULLFEED9707735) on April 28, 2026, and is solely responsible for the information contained therein.